Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II, open label, two-centered study for evaluation of the addition of
nivolumab and cetuximab after chemoradiation as a neoadjuvant treatment for locally advanced
esophageal squamous cell carcinoma patients. Subjects must have received no prior treatment
for esophageal cancer (chemotherapy, radiotherapy or surgery) and no prior treatment with
checkpoint inhibitors.
Eligible subjects will receive induction chemotherapy with cetuximab for a period of 4 weeks,
chemoradiation with cetuximab for a period of 6 weeks, 3 cycles of immunotherapy (nivolumab +
cetuximab) for a period of 6 weeks, and will undergo surgery at the end of the treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Baruch Brenner
Collaborators:
Bristol-Myers Squibb Merck Serono International SA